search
Back to results

Beta-Lactam InfusioN Group Study (BLING III)

Primary Purpose

Sepsis

Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Continuous infusion
Intermittent infusion
Sponsored by
The George Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis focused on measuring Sepsis, Beta-lactam antibiotics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Documented site of infection or strong suspicion of infection
  2. At the time of the assessment of suitability for the study, the treating physician expects the patient will require treatment in the ICU that extends beyond the next calendar day
  3. The treating physician has chosen piperacillin-tazobactam or meropenem to treat the episode of infection
  4. The treating physician is uncertain if administration of the chosen antibiotic by intermittent or continuous infusion is superior

  5. One or more organ dysfunction entry criteria in the previous 24 hours

    • i. Mean arterial pressure < 60 mmHg for at least 1 hour
    • ii. Vasopressors required for > 4 hours
    • iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour
    • iv. Serum creatinine concentration > 220 µmol/L

Exclusion Criteria:

  1. Age less than 18 years
  2. Receipt of piperacillin-tazobactam or meropenem for more than 24 hours during current infectious episode
  3. Patients who are known or suspected to be pregnant
  4. Patient has a known allergy to piperacillin-tazobactam or meropenem or penicillin
  5. Receiving renal replacement therapy at the time of assessment for eligibility
  6. The treating physician is not committed to provision of advanced life-support, including mechanical ventilation, dialysis and vasopressor administration, for at least the next 48 hours
  7. Death is deemed imminent and inevitable
  8. The patient has previously been enrolled in BLING III

Sites / Locations

  • Bankstown Hospital
  • Blacktown Hospital
  • Royal Prince Alfred Hospital
  • St Vincents Hosptial
  • Gosford Hospital
  • John Hunter Hospital
  • Royal North Shore Hospital
  • St George Hospital
  • Westmead Hospital
  • Royal Darwin Hospital
  • The Wesley Hospital
  • Royal Brisbane and Women's Hospital
  • Caboolture Hospital
  • Logan Hospital
  • Redcliffe Hospital
  • Gold Coast University Hospital
  • Princess Alexandra Hospital
  • The Queen Elizabeth Hospital
  • Lyell McEwin Hospital
  • Royal Hobart Hospital
  • Bendigo Hospital
  • Box Hill Hospital - Eastern Health
  • Geelong University Hospital
  • Austin Hospital
  • Royal Melbourne Hospital
  • Hôpital Erasme
  • ZNA Stuivenberg
  • Universitair ziekenhuis Antwerpen
  • Universitair ziekenhuis Brussel
  • Civil Hospital Marie Curie
  • Maria Middelares
  • Universitair ziekenhuis Gent
  • Clinique Saint Pierre
  • Ch Salon de Provence
  • Nimes University Hospital
  • Centre Hospitalier Henri Duffaut
  • Brabois
  • Poitiers University Hospital
  • Hospital Universiti Sains Malaysia
  • University Malaya Medical Centre
  • Auckland City Hospital - CVICU
  • Auckland City Hospital - DCCM
  • Middlmore Hospital
  • Christchurch Hospital
  • Waikato Hospital
  • Wellington Hospital
  • Helsingborg Hospital
  • Skane Lund University Hospital
  • Skane University Malmo Hospital
  • Royal Berkshire Hospital
  • Kings College Hospital
  • Princess Royal University Hospital
  • Stoke Mandeville Hospital
  • Milton Keynes University Hospital
  • Countess of Chester Hospital
  • Dorset County Hospital
  • Poole Hospital
  • University Hospital of North Tees
  • Ipswich Hospital
  • Darent Valley Hospital
  • Maidstone Hospital
  • Derriford Hospital
  • Broomfield Hospital
  • Golden Jubilee National Hospital
  • Royal Bolton Hospital
  • Charing Cross Hospital
  • Basingstoke and North Hampshire Hospital
  • Queen Alexandra Hospital
  • Southampton General Hospital
  • Royal Hampshire County Hospital
  • Hereford County Hospital
  • Watford General Hospital
  • Medway Maritime Hospital
  • Kingston Hospital
  • Tunbridge Wells Hospital
  • Blackpool Victoria Hospital
  • The Royal Marsden
  • Guy's & St Thomas' Hospital London
  • St Georges Hospital
  • The Royal London Hospital
  • Royal Victoria Infirmary
  • Newcastle Freeman Hospital
  • The Queens Medical Centre
  • Kingsmill Hospital
  • St Marys Hospital
  • Whiston Hospital
  • Hammersmith Hospital
  • James Cook University Hospital South Tees
  • Frimley Park Hospital
  • Royal Surrey County Hospital
  • Sunderland Royal Hospital
  • University Hospital of Wales
  • University Hospital Coventry & Warwickshire
  • Queen Elizabeth Medical Centre
  • Pinderfields General Hospital
  • Bristol Royal Infirmary
  • Northumbria Specialist Emergency Hospital
  • Ninewells Hospital
  • Glasgow Royal Infirmary
  • Hull Royal Infirmary
  • Whittington Health
  • Queen's Hospital
  • Salford Royal Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Continuous Infusion

Intermittent infusion

Arm Description

The prescribed Beta-lactam is administered by a continuous infusion.

the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes

Outcomes

Primary Outcome Measures

All-cause mortality
Patient mortality status assessed at 90 days after randomisation

Secondary Outcome Measures

Clinical Cure
Clinical cure will be defined as the completion of the beta-lactam antibiotic treatment course (on or prior to Day 14) without recommencement of antibiotic therapy within 48 hours of cessation. Participants discharged from hospital within 14 days following randomisation will be considered to meet the definition of clinical cure. Participants who decease while receiving the antibiotic treatment course or where antibiotic therapy is ceased in the setting of death being deemed imminent and inevitable, will be assessed as not meeting the criteria for clinical cure.
New acquisition, colonisation or infection
New acquisition, colonisation or infection with an Multi-resistant organism (MRO) or Clostridium difficile diarrhoea
All cause ICU mortality
Patient mortality status assessed at ICU discharge
All cause hospital mortality
Patient mortality status assessed at hospital discharge

Full Information

First Posted
June 5, 2017
Last Updated
January 21, 2023
Sponsor
The George Institute
Collaborators
National Health and Medical Research Council, Australia, Australian and New Zealand Intensive Care Society Clinical Trials Group
search

1. Study Identification

Unique Protocol Identification Number
NCT03213990
Brief Title
Beta-Lactam InfusioN Group Study
Acronym
BLING III
Official Title
A Phase III Randomised Controlled Trial of Continuous Beta-lactam Infusion Compared With Intermittent Beta-lactam Dosing in Critically Ill Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 26, 2018 (Actual)
Primary Completion Date
April 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The George Institute
Collaborators
National Health and Medical Research Council, Australia, Australian and New Zealand Intensive Care Society Clinical Trials Group

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to find out whether continuous infusion of beta-lactam antibiotics or intermittent infusion or beta-lactam antibiotics, offers more health advantages to patients or if there is no difference. The investigators will be looking to see whether patients receiving beta-lactams via one administration method or the other have a better chance of recovering from their illness. They will also be looking at long term outcomes such as quality-of-life and healthcare resource use. Sepsis is caused by toxic substances (toxins) from bacteria and other organism entering the bloodstream from a site of infection. In some people, the infection can progress to sepsis and septic shock where the functions of organs in the body are affected. Patients suffering from sepsis and septic shock are commonly managed in the intensive care unit (ICU) where they are prescribed antibiotics as standard therapy, as well as other therapies to support the functions of the body. Beta-lactam antibiotics are a group of antibiotics commonly used to treat infection in patients with sepsis and septic shock. Currently, beta-lactam antibiotics are most commonly given to patients be intermittent infusions, that is, given at regular intervals throughout 24 hours. New research suggests that giving beta-lactam antibiotics as a continuous infusion may mean that antibiotic concentrations in the blood remain more consistent and may be more effective at killing bacteria. However, the benefit to the patient by giving beta-lactams via continuous infusion has not been tested in a high-quality, large clinical trial.
Detailed Description
Aim To conduct a multicentre randomised, controlled trial (RCT) to determine whether continuous infusion of a beta-lactam antibiotic (piperacillin-tazobactam or meropenem) results in decreased all cause Day 90 mortality compared with intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis. Hypothesis The BLING III Study will test the hypothesis that patients managed in the ICU with sepsis, the administration of beta-lactam antibiotics via continuous infusion decreases Day 90 mortality compared with intermittent infusion Design This BLING III study is a prospective, multicentre, open, phase III, RCT. Participants commenced on one of two beta-lactam antibiotics (piperacillin-tazobactam or meropenem) will be randomised to receive the beta-lactam antibiotic via either continuous infusion or intermittent infusion over 30 minutes for the treatment course while in the ICU for up to 90 days after randomisation. For participants where the beta-lactam antibiotic is subsequently changed from piperacillin-tazobactam to meropenem or vice versa for ongoing treatment of the infectious episode, the new prescription will continue to be administered in the allocated method (continuous infusion or intermittent infusion over 30 minutes). Permuted block randomisation with variable block sizes and stratified by site will be conducted via a password-protected, secure web-based interface. The primary endpoint for this trial will be death from all causes at 90 days. 7,000 patients will be enrolled into this study from approximately 70 ICUs worldwide, with approximately 35 ICUs in Australian and New Zealand hospitals. For eligible patients, the administration method of beta-lactam antibiotic, either piperacillin-tazobactam or meropenem, will be randomised to either continuous infusion or intermittent infusion over 30 minutes. The choice of beta-lactam antibiotic and the dose and dosing interval (i.e. the dose the patient will receive in 24 hours) will be determined by the treating physician prior to randomisation. For all patients, data will be collected at baseline and daily whilst in the ICU. Patients will be followed up to day 14, regardless of location in the hospital, to determine test of cure and to identify new acquisition, colonisation or infection with an multi-resistant organism. Additional follow up will occur at 90 days post randomisation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
Keywords
Sepsis, Beta-lactam antibiotics

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
7203 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Continuous Infusion
Arm Type
Other
Arm Description
The prescribed Beta-lactam is administered by a continuous infusion.
Arm Title
Intermittent infusion
Arm Type
Other
Arm Description
the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes
Intervention Type
Other
Intervention Name(s)
Continuous infusion
Intervention Description
Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
Intervention Type
Other
Intervention Name(s)
Intermittent infusion
Intervention Description
Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
Primary Outcome Measure Information:
Title
All-cause mortality
Description
Patient mortality status assessed at 90 days after randomisation
Time Frame
90 Days after randomisation
Secondary Outcome Measure Information:
Title
Clinical Cure
Description
Clinical cure will be defined as the completion of the beta-lactam antibiotic treatment course (on or prior to Day 14) without recommencement of antibiotic therapy within 48 hours of cessation. Participants discharged from hospital within 14 days following randomisation will be considered to meet the definition of clinical cure. Participants who decease while receiving the antibiotic treatment course or where antibiotic therapy is ceased in the setting of death being deemed imminent and inevitable, will be assessed as not meeting the criteria for clinical cure.
Time Frame
Day 14 post randomisation
Title
New acquisition, colonisation or infection
Description
New acquisition, colonisation or infection with an Multi-resistant organism (MRO) or Clostridium difficile diarrhoea
Time Frame
up to 14 days post randomisation or hospital discharge, whichever is sooner
Title
All cause ICU mortality
Description
Patient mortality status assessed at ICU discharge
Time Frame
up to 90 days
Title
All cause hospital mortality
Description
Patient mortality status assessed at hospital discharge
Time Frame
up to 90 days
Other Pre-specified Outcome Measures:
Title
ICU length of stay
Description
Patient assessment of time spent in the ICU
Time Frame
up to 90 days
Title
Hospital length of stay
Description
Patient assessment of time spent in hospital.
Time Frame
up to 90 days
Title
Quality of life
Description
Quality of life measured with the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L)
Time Frame
90 days after randomisation
Title
Health services use
Description
Additional follow up at Day 90 for the purpose of economic evaluation will be conducted for Australian, New Zealand and sites from participating regions only. Follow up at Day 90 will include recording readmission to hospital and ICU within 90 days and will assess quality of life and functional capacity using the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) questionnaire (if not deceased).38 The consent document used at participating sites will detail the inclusion of a quality of life questionnaire at Day 90.
Time Frame
up to 90 days after randomisation
Title
Cost effectiveness analysis
Description
A cost-effectiveness analysis at 90 days following randomisation will be conducted as a nested cohort in Australian, New Zealand and other potential regional sites. Cost data will be derived from health care utilisation to Day 90, estimated through standard per diem ICU and hospital costs. The analysis will be conducted from a health care payer perspective, comparing health care utilisation costs and quality-adjusted life years gained (measured by the EQ-5D-5L) between treatment arms. Where feasible, the cost-effectiveness analysis will be conducted in other country-specific regions. Depending on the outcome from the primary trial, several further analyses are planned including a longer-term cohort study and a modelled economic evaluation. The BLING III cost-effectiveness analysis will be informed by a separate Statistical Analysis Plan.
Time Frame
up to 90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Documented site of infection or strong suspicion of infection At the time of the assessment of suitability for the study, the treating physician expects the patient will require treatment in the ICU that extends beyond the next calendar day The treating physician has chosen piperacillin-tazobactam or meropenem to treat the episode of infection The treating physician is uncertain if administration of the chosen antibiotic by intermittent or continuous infusion is superior One or more organ dysfunction entry criteria in the previous 24 hours i. Mean arterial pressure < 60 mmHg for at least 1 hour ii. Vasopressors required for > 4 hours iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour iv. Serum creatinine concentration > 220 µmol/L Exclusion Criteria: Age less than 18 years Receipt of piperacillin-tazobactam or meropenem for more than 24 hours during current infectious episode Patients who are known or suspected to be pregnant Patient has a known allergy to piperacillin-tazobactam or meropenem or penicillin Receiving renal replacement therapy at the time of assessment for eligibility The treating physician is not committed to provision of advanced life-support, including mechanical ventilation, dialysis and vasopressor administration, for at least the next 48 hours Death is deemed imminent and inevitable The patient has previously been enrolled in BLING III
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Lipman
Organizational Affiliation
The George Institute
Official's Role
Study Chair
Facility Information:
Facility Name
Bankstown Hospital
City
Bankstown
State/Province
New South Wales
ZIP/Postal Code
2200
Country
Australia
Facility Name
Blacktown Hospital
City
Blacktown
State/Province
New South Wales
ZIP/Postal Code
2148
Country
Australia
Facility Name
Royal Prince Alfred Hospital
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Facility Name
St Vincents Hosptial
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Facility Name
Gosford Hospital
City
Gosford
State/Province
New South Wales
ZIP/Postal Code
2250
Country
Australia
Facility Name
John Hunter Hospital
City
New Lambton Heights
State/Province
New South Wales
ZIP/Postal Code
2305
Country
Australia
Facility Name
Royal North Shore Hospital
City
Saint Leonards
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Facility Name
St George Hospital
City
Sydney
State/Province
New South Wales
Country
Australia
Facility Name
Westmead Hospital
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Facility Name
Royal Darwin Hospital
City
Casuarina
State/Province
Northern Territory
ZIP/Postal Code
0811
Country
Australia
Facility Name
The Wesley Hospital
City
Auchenflower
State/Province
Queensland
ZIP/Postal Code
4066
Country
Australia
Facility Name
Royal Brisbane and Women's Hospital
City
Brisbane
State/Province
Queensland
Country
Australia
Facility Name
Caboolture Hospital
City
Caboolture
State/Province
Queensland
ZIP/Postal Code
4510
Country
Australia
Facility Name
Logan Hospital
City
Meadowbrook
State/Province
Queensland
ZIP/Postal Code
4131
Country
Australia
Facility Name
Redcliffe Hospital
City
Redcliffe
State/Province
Queensland
ZIP/Postal Code
4020
Country
Australia
Facility Name
Gold Coast University Hospital
City
Southport
State/Province
Queensland
ZIP/Postal Code
4215
Country
Australia
Facility Name
Princess Alexandra Hospital
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Facility Name
The Queen Elizabeth Hospital
City
Adelaide
State/Province
South Australia
Country
Australia
Facility Name
Lyell McEwin Hospital
City
Elizabeth Vale
State/Province
South Australia
ZIP/Postal Code
5112
Country
Australia
Facility Name
Royal Hobart Hospital
City
Hobart
State/Province
Tasmania
ZIP/Postal Code
7001
Country
Australia
Facility Name
Bendigo Hospital
City
Bendigo
State/Province
Victoria
ZIP/Postal Code
3550
Country
Australia
Facility Name
Box Hill Hospital - Eastern Health
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Geelong University Hospital
City
Geelong
State/Province
Victoria
ZIP/Postal Code
3220
Country
Australia
Facility Name
Austin Hospital
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Facility Name
Royal Melbourne Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Facility Name
Hôpital Erasme
City
Brussels
State/Province
Anderlecht
ZIP/Postal Code
, 1070
Country
Belgium
Facility Name
ZNA Stuivenberg
City
Antwerpen
ZIP/Postal Code
2060
Country
Belgium
Facility Name
Universitair ziekenhuis Antwerpen
City
Antwerp
ZIP/Postal Code
2610
Country
Belgium
Facility Name
Universitair ziekenhuis Brussel
City
Brussels
ZIP/Postal Code
1090
Country
Belgium
Facility Name
Civil Hospital Marie Curie
City
Charleroi
Country
Belgium
Facility Name
Maria Middelares
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Universitair ziekenhuis Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Clinique Saint Pierre
City
Ottignies
ZIP/Postal Code
1340
Country
Belgium
Facility Name
Ch Salon de Provence
City
Salon-de-Provence
State/Province
Bouche Du Rhone
ZIP/Postal Code
13300
Country
France
Facility Name
Nimes University Hospital
City
Nîmes
State/Province
Nimes
ZIP/Postal Code
30900
Country
France
Facility Name
Centre Hospitalier Henri Duffaut
City
Avignon
State/Province
Vaucluse
ZIP/Postal Code
84902
Country
France
Facility Name
Brabois
City
Nancy
Country
France
Facility Name
Poitiers University Hospital
City
Poitiers
Country
France
Facility Name
Hospital Universiti Sains Malaysia
City
Kota Bharu
State/Province
Kelantan
ZIP/Postal Code
16150
Country
Malaysia
Facility Name
University Malaya Medical Centre
City
Kuala Lumpur
State/Province
Selangor
ZIP/Postal Code
59100
Country
Malaysia
Facility Name
Auckland City Hospital - CVICU
City
Auckland
ZIP/Postal Code
1142
Country
New Zealand
Facility Name
Auckland City Hospital - DCCM
City
Auckland
ZIP/Postal Code
1142
Country
New Zealand
Facility Name
Middlmore Hospital
City
Auckland
Country
New Zealand
Facility Name
Christchurch Hospital
City
Christchurch
ZIP/Postal Code
8011
Country
New Zealand
Facility Name
Waikato Hospital
City
Hamilton
ZIP/Postal Code
3240
Country
New Zealand
Facility Name
Wellington Hospital
City
Wellington
ZIP/Postal Code
6021
Country
New Zealand
Facility Name
Helsingborg Hospital
City
Helsingborg
ZIP/Postal Code
25223
Country
Sweden
Facility Name
Skane Lund University Hospital
City
Lund
ZIP/Postal Code
22242
Country
Sweden
Facility Name
Skane University Malmo Hospital
City
Malmo
ZIP/Postal Code
21421
Country
Sweden
Facility Name
Royal Berkshire Hospital
City
Reading
State/Province
Berkshire
ZIP/Postal Code
RG1 5AN
Country
United Kingdom
Facility Name
Kings College Hospital
City
London
State/Province
Brixton
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Facility Name
Princess Royal University Hospital
City
Orpington
State/Province
Bromley
ZIP/Postal Code
BR6 8ND
Country
United Kingdom
Facility Name
Stoke Mandeville Hospital
City
Aylesbury
State/Province
Buckinghamshire
ZIP/Postal Code
HP21 8AL
Country
United Kingdom
Facility Name
Milton Keynes University Hospital
City
Milton Keynes
State/Province
Buckinghamshire
ZIP/Postal Code
MK6 5LD
Country
United Kingdom
Facility Name
Countess of Chester Hospital
City
Chester
State/Province
Cheshire
ZIP/Postal Code
CH21UL
Country
United Kingdom
Facility Name
Dorset County Hospital
City
Dorchester
State/Province
Dorset
ZIP/Postal Code
DT1 2JY
Country
United Kingdom
Facility Name
Poole Hospital
City
Poole
State/Province
Dorset
ZIP/Postal Code
BH15 2JB
Country
United Kingdom
Facility Name
University Hospital of North Tees
City
Stockton-on-Tees
State/Province
Durham
ZIP/Postal Code
TS19 8PE
Country
United Kingdom
Facility Name
Ipswich Hospital
City
Ipswich
State/Province
East Suffolk
ZIP/Postal Code
IP4 5PD
Country
United Kingdom
Facility Name
Darent Valley Hospital
City
Dartford
State/Province
England
ZIP/Postal Code
DA28DA
Country
United Kingdom
Facility Name
Maidstone Hospital
City
Maidstone
State/Province
England
ZIP/Postal Code
ME169QQ
Country
United Kingdom
Facility Name
Derriford Hospital
City
Plymouth
State/Province
England
ZIP/Postal Code
PL68DH
Country
United Kingdom
Facility Name
Broomfield Hospital
City
Chelmsford
State/Province
Essex
ZIP/Postal Code
CM1 7ET
Country
United Kingdom
Facility Name
Golden Jubilee National Hospital
City
Clydebank
State/Province
Glasgow
ZIP/Postal Code
G81 4HX
Country
United Kingdom
Facility Name
Royal Bolton Hospital
City
Bolton
State/Province
Greater Manchester
ZIP/Postal Code
BL4 0JR
Country
United Kingdom
Facility Name
Charing Cross Hospital
City
London
State/Province
Hammersmith
ZIP/Postal Code
SW6 8RF
Country
United Kingdom
Facility Name
Basingstoke and North Hampshire Hospital
City
Basingstoke
State/Province
Hampshire
ZIP/Postal Code
RG24 9NA
Country
United Kingdom
Facility Name
Queen Alexandra Hospital
City
Portsmouth
State/Province
Hampshire
ZIP/Postal Code
PO6 3LY
Country
United Kingdom
Facility Name
Southampton General Hospital
City
Southampton
State/Province
Hampshire
ZIP/Postal Code
SO16 6YD
Country
United Kingdom
Facility Name
Royal Hampshire County Hospital
City
Winchester
State/Province
Hampshire
ZIP/Postal Code
SO22 5DG
Country
United Kingdom
Facility Name
Hereford County Hospital
City
Hereford
State/Province
Herefordshire
ZIP/Postal Code
HR1 2ER
Country
United Kingdom
Facility Name
Watford General Hospital
City
Watford
State/Province
Hertfordshire
ZIP/Postal Code
WD18 0HB
Country
United Kingdom
Facility Name
Medway Maritime Hospital
City
Gillingham
State/Province
Kent
ZIP/Postal Code
ME7 5NY
Country
United Kingdom
Facility Name
Kingston Hospital
City
Kingston Upon Thames
State/Province
Kent
ZIP/Postal Code
KT2 7QB
Country
United Kingdom
Facility Name
Tunbridge Wells Hospital
City
Tunbridge Wells
State/Province
Kent
ZIP/Postal Code
TN2 4QJ
Country
United Kingdom
Facility Name
Blackpool Victoria Hospital
City
Blackpool
State/Province
Lancashire
ZIP/Postal Code
FY3 8NR
Country
United Kingdom
Facility Name
The Royal Marsden
City
Chelsea
State/Province
London
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Facility Name
Guy's & St Thomas' Hospital London
City
Lambeth
State/Province
London
ZIP/Postal Code
SE1 7EH
Country
United Kingdom
Facility Name
St Georges Hospital
City
Tooting
State/Province
London
ZIP/Postal Code
SW17 0QT
Country
United Kingdom
Facility Name
The Royal London Hospital
City
Whitechapel
State/Province
London
ZIP/Postal Code
E1 1BB
Country
United Kingdom
Facility Name
Royal Victoria Infirmary
City
Newcastle
State/Province
Northhumberland
ZIP/Postal Code
NE1 4LP
Country
United Kingdom
Facility Name
Newcastle Freeman Hospital
City
Newcastle
State/Province
Northumberland
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Facility Name
The Queens Medical Centre
City
Nottingham
State/Province
Nottinghamshire
ZIP/Postal Code
NG7 2UH
Country
United Kingdom
Facility Name
Kingsmill Hospital
City
Sutton In Ashfield
State/Province
Nottinghamshire
ZIP/Postal Code
NG17 4JL
Country
United Kingdom
Facility Name
St Marys Hospital
City
London
State/Province
Paddington
ZIP/Postal Code
W2 1NY
Country
United Kingdom
Facility Name
Whiston Hospital
City
Rainhill
State/Province
Prescot
ZIP/Postal Code
L35 5DR
Country
United Kingdom
Facility Name
Hammersmith Hospital
City
London
State/Province
Shepherds Bush
ZIP/Postal Code
W12 0HS,
Country
United Kingdom
Facility Name
James Cook University Hospital South Tees
City
Middlesbrough
State/Province
South Tees
ZIP/Postal Code
TS4 3BW
Country
United Kingdom
Facility Name
Frimley Park Hospital
City
Frimley
State/Province
Surrey
ZIP/Postal Code
GU16 7UJ
Country
United Kingdom
Facility Name
Royal Surrey County Hospital
City
Guildford
State/Province
Surrey
ZIP/Postal Code
GU2 7XX
Country
United Kingdom
Facility Name
Sunderland Royal Hospital
City
Sunderland
State/Province
Tyne And Wear
ZIP/Postal Code
SR4 7TP
Country
United Kingdom
Facility Name
University Hospital of Wales
City
Cardiff
State/Province
Wales
ZIP/Postal Code
CF14 4XW
Country
United Kingdom
Facility Name
University Hospital Coventry & Warwickshire
City
Coventry
State/Province
Warwickshire
ZIP/Postal Code
CV2 2DX
Country
United Kingdom
Facility Name
Queen Elizabeth Medical Centre
City
Birmingham
State/Province
West Midlands
ZIP/Postal Code
B12 2TH
Country
United Kingdom
Facility Name
Pinderfields General Hospital
City
Wakefield
State/Province
West Yorkshire
ZIP/Postal Code
WF1 4DG
Country
United Kingdom
Facility Name
Bristol Royal Infirmary
City
Bristol
ZIP/Postal Code
BS1 3NU
Country
United Kingdom
Facility Name
Northumbria Specialist Emergency Hospital
City
Cramlington
Country
United Kingdom
Facility Name
Ninewells Hospital
City
Dundee
Country
United Kingdom
Facility Name
Glasgow Royal Infirmary
City
Glasgow
Country
United Kingdom
Facility Name
Hull Royal Infirmary
City
Hull
ZIP/Postal Code
HU3 2JZ
Country
United Kingdom
Facility Name
Whittington Health
City
London
ZIP/Postal Code
N19 5NF
Country
United Kingdom
Facility Name
Queen's Hospital
City
Romford
Country
United Kingdom
Facility Name
Salford Royal Hospital
City
Salford
ZIP/Postal Code
M6 8HD
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Yet to be decided
Citations:
PubMed Identifier
30857514
Citation
Lipman J, Brett SJ, De Waele JJ, Cotta MO, Davis JS, Finfer S, Glass P, Knowles S, McGuinness S, Myburgh J, Paterson DL, Peake S, Rajbhandari D, Rhodes A, Roberts JA, Shirwadkar C, Starr T, Taylor C, Billot L, Dulhunty JM. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Crit Care Resusc. 2019 Mar;21(1):63-68.
Results Reference
derived

Learn more about this trial

Beta-Lactam InfusioN Group Study

We'll reach out to this number within 24 hrs